Bloomberg BNA's Pharmaceutical Law & Industry Report helps you stay informed of regulatory and litigation developments affecting the pharmaceutical and biotech industries....
The Department of Justice April 14 announced that a former drug company attorney has been re-indicted on charges of obstruction and making false statements related to promotions of a pharmaceutical product (United States v. Stevens, D. Md., No. 8:10-cr-694-RWT, indictment 4/13/11).
In March, a judge in the U.S. District Court for the District of Maryland threw out the case against Lauren Stevens, who was an in-house counsel for GlaxoSmithKline. Judge Roger W. Titus found that prosecutors erroneously and prejudicially instructed the grand jury regarding the advice of counsel defense in the case.
The new indictment was returned April 13, DOJ said in a brief statement. DOJ noted that the drug company has not been charged with a crime.
The government said Stevens, a resident of Durham, N.C., is charged with one count of obstructing an official proceeding, one count of concealing and falsifying documents to influence a federal agency, and four counts of making false statements to the Food and Drug Administration. “The indictment returned late Wednesday in the District of Maryland contains essentially the same charges that were brought against Stevens in November 2010,” DOJ said.
Stevens's case involved GSK's promotion of its antidepressant drug Wellbutrin. In the original indictment from 2010, the company and its drug product were not named, but the government said the case involved promotion of a drug for off-label or unapproved uses. In the news release issued April 14, however, DOJ said the new indictment identifies GlaxoSmithKline as Stevens's employer at the time of the alleged obstruction and false statements.
The judge set a tentative trial date of April 26, DOJ said.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)